Compare Biogen Inc (BIIB) vs Danaos Corporation (DAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Danaos Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Danaos Corporation trades at $138.99 (market cap $2.46B). The key difference: Biogen Inc is far larger — about 12.2× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DAC | |
|---|---|---|
Market Cap | $30.13B | $2.46B |
Sector | Health | Technology |
52-Week High | $216.63 | $143.15 |
52-Week Low | $128.93 | $84.05 |
Enterprise Value | $37.20B | $2.44B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Danaos Corporation (DAC) trades at $139.81, up 1.08% with bullish technical signals and strong fundamentals. The stock shows robust profitability with a 51.26% net margin and trades at attractive valuations including a P/E of 4.57 and P/B of 0.61. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $7.29 surpassing the $6.80 estimate. The company maintains a record $4.6 billion contracted revenue backlog and pays a $0.90 quarterly dividend.
Outlook remains positive given earnings momentum and undervaluation, though risks include shipping rate volatility and capital expenditure demands. Analyst consensus is evenly split between Buy and Hold ratings, reflecting cautious optimism amid sector cyclicality. The stock's technical strength near key resistance at $138 suggests potential for further gains if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
